All Regenerative Medicine articles – Page 3
-
ArticleGamma delta T cells: a rising star in cancer therapy
Gamma delta (γδ) T cells comprise a distinct and powerful subpopulation of T cells, bridging innate and adaptive immunity, that holds great promise for treating cancer. IN8Bio co-founder and CEO William Ho and COO Kate Rochlin discuss what makes γδ T cells unique, how preclinical research suggests their antitumour activity ...
-
ArticleUnderstanding how macrophages direct tissue regeneration
Distinct macrophage signatures that align specifically with regeneration could offer novel therapies to enhance wound healing.
-
ArticleThe science of ageing and restoring healthspan
Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. Life Biosciences are specifically focused on restoring and prolonging one’s ...
-
NewsTelomeres linked to higher dementia risk
A study proposes that shorter telomeres at the tips of chromosomes in white blood cells might indicate an elevated risk of dementia.
-
ReportBeyond the lab: cell & gene therapy
The launch of our new series, "Beyond the Lab," promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Our inaugural report is an exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery.
-
ArticleThe promise of iPSC-based multi-cell therapeutics
Drug Target Review’s Taylor Mixides exclusively interviews Matt Angel, PhD, Chief Executive Officer and President of Eterna Therapeutics, about a potential new class of cell therapies that may play an important role in the development of new cancer treatments.
-
NewsHow do cells control the secretion of mucin and insulin?
Spanish researchers looking at two crucial proteins uncover how cells release mucin and insulin, leading to new methods to reset deregulation.
-
ArticleWomen in STEM with Dr Jo Brewer
Come and join us for our monthly series highlighting Women in STEM. We are excited to present the latest edition for June, featuring an exclusive interview with Dr Jo Brewer, Chief Scientific Officer at Adaptimmune. With a remarkable 15-years of experience in cell therapy, Jo's passion for cells has been ...
-
ArticleNeoantigen-directed cancer treatment
This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, explores research on T-cell therapy for cancer, which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.
- Previous Page
- Page1
- Page2
- Page3
- Next Page